 NEW YORK, June 01, 2021 GLOBE NEWSWIRE -- Immunovant, Inc. Nasdaq: IMVT, a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today provided a corporate update and reported financial results for its fiscal fourth quarter and fiscal year ended March 31, 2021. 